Cipollone v. Liggett Group, Inc.
File:SGR History.webm Cipollone v. Liggett Group, Inc. was a landmark United States Supreme Court case that addressed the issue of preemption in the context of tobacco litigation. The case was decided on June 24, 1992, and is reported at 505 U.S. 504 (1992).
Background[edit | edit source]
The case was brought by Rose Cipollone, who had started smoking in the 1940s and later developed lung cancer. Cipollone sued several tobacco companies, including the Liggett Group, alleging that they were liable for her illness due to negligence, breach of warranty, and fraudulent misrepresentation.
Legal Issues[edit | edit source]
The primary legal issue in Cipollone v. Liggett Group, Inc. was whether the Federal Cigarette Labeling and Advertising Act of 1965 and its subsequent amendments preempted state law claims against tobacco companies. The Act required specific health warnings on cigarette packages and restricted the ability of states to impose additional regulations.
Supreme Court Decision[edit | edit source]
The Supreme Court delivered a fragmented decision, with no single opinion commanding a majority. The Court held that certain state law claims were preempted by the federal statute, while others were not. Specifically, the Court found that claims based on failure to warn and fraudulent misrepresentation were preempted, but claims based on express warranty, intentional fraud, and conspiracy were not.
Impact[edit | edit source]
The decision in Cipollone v. Liggett Group, Inc. had significant implications for future tobacco litigation and the doctrine of preemption. It clarified the extent to which federal law can limit state law claims, particularly in the context of regulated industries.
See Also[edit | edit source]
- Preemption (law)
- Federal Cigarette Labeling and Advertising Act
- Tobacco litigation
- United States Supreme Court cases
References[edit | edit source]
External Links[edit | edit source]
| Cipollone v. Liggett Group, Inc. | |
|---|---|
 | |
| Full case name | Cipollone v. Liggett Group, Inc. |
 | This law-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
